The effects of anagrelide on human megakaryocytopoiesis

Anagrelide, an inhibitor of platelet aggregation, decreases the number of platelets in normal subjects and in patients with myeloproliferative disorders. We describe studies aimed at discovering the general mechanism(s) by which anagrelide acts. We examined three hypotheses: (1) anagrelide shortens...

Full description

Saved in:

Bibliographic Details
Published in:	British journal of haematology Vol. 99; no. 1; pp. 174 - 180
Main Authors:	Solberg Jr, Lawrence A., Tefferi, Ayalew, Oles, Karl J., Tarach, Jerzy S., Petitt, Robert M., Forstrom, Lee A., Silverstein, Murray N.
Format:	Journal Article
Language:	English
Published:	Oxford, UK Blackwell Science Ltd 01-10-1997 Blackwell
Subjects:	Adult Biological and medical sciences Blood Platelets - cytology Blood Platelets - drug effects Blood. Blood coagulation. Reticuloendothelial system Cell Division Cell Survival Cells, Cultured Cellular Senescence - drug effects digital imaging analysis Female glycoprotein IIb/IIIa haemopoiesis Humans Male Medical sciences megakaryocyte Megakaryocytes - cytology Megakaryocytes - drug effects Middle Aged Pharmacology. Drug treatments Platelet Aggregation Inhibitors - pharmacology Quinazolines - pharmacology Stem Cells Human Megakaryocytopoiesis Hematopoiesis Stem cell Hematopoietic cell Megakaryocyte Digital image Cell differentiation Mechanism of action Antiplatelet agent Anagrelide
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!